Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT07521046
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ropeginterferon alfa- 2b — DRUG
    Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.
  • Ruxolitinib — DRUG
    Ruxolitinib will be administered per standard of care.

Study Details

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2029
Completion
May 31, 2030

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: All Patients
    This study will investigate the safety and tolerability of ropeginterferon alfa- 2b added on to standard of care ruxolitinib.

Primary Outcome Measure

The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer Institute at University of UtahSalt Lake CityUtah84112
Nicole Fisher
[email protected]
801-587-7604

Find similar trials in Salt Lake City, UT

By research site
Huntsman Cancer Institute at University of Utah· Salt Lake City, UT

Related Studies